“All device-related adverse events were anticipated, transient, nonserious ocular events that resolved without sequelae. “Our study findings strongly suggest, screening for MGD and treating underlying gland dysfunction is an appropriate protocol for all patients, even in the absence of dry eye symptoms.” Holland, MD, a study investigator and author of the publication. “Because MGD is chronic and progressive, it has long been suspected that early intervention is likely to yield increased benefits,” said Edward J.
Whether alone or complemented with supplemental periodic interventions, LipiFlow optimizes outcomes for dry eye sufferers,” said Joseph Boorady, CEO of TearScience. LipiFlow provides long-term improvement in meibomian gland function and dry eye symptoms. “The sustained results shown in this study, are evidence that LipiFlow’s inner-lid heat with combined vectored pulsation is uniquely effective. The mean improvement of meibomian gland function and dry eye symptoms have been frequently studied, documented and reviewed.2 What is novel about this study is that the effect of a single LipiFlow treatment was monitored and, on average, sustained through the 12-month study period.Īt 12 months 86% of patients had received only a single LipiFlow treatment and did not require additional prescription therapy for dry eye symptoms. For most patients, successful treatment of MGD requires removal of obstruction. MGD, is prevalent, progressive, obstructive and considered the most common cause of Dry Eye. The study also concluded that early LipiFlow intervention for meibomian gland dysfunction is associated with improved treatment outcomes. ─ ─ TearScience, a privately held medical device company and manufacturer of LipiFlow® for treatment of MGD, announced publication1 of a seminal prospective, multicenter clinical trial showing a single LipiFlow treatment can deliver a sustained mean improvement in meibomian gland function and dry eye symptoms through 12 months.
Early LipiFlow intervention for MGD is associated with improved treatment outcomes.
Source LipiFlow is the only single-dose treatment for Meibomian Gland Dysfunction (MGD) shown to improve gland function and dry eye symptoms with sustained duration. New Single Dose Treatment for Dry Eyes! A Single LipiFlow® Treatment Demonstrates Sustained Improvement in Gland Function and Symptoms in Patients with MGD and Dry Eye in a Long Term Study
0 kommentar(er)
